Personalis Inc

NASDAQ:PSNLUnited States

Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Contact Information

Headquarters

6600 Dumbarton CircleFREMONT, CA, United States 94555

Phone

650-752-1300

Fax

302-531-3150

Executives

Independent Chairman of the Board

Karin Eastham

President, Chief Executive Officer, Director

Christopher Hall

Chief Financial Officer, Chief Operating Officer, Senior Vice President

Aaron Tachibana

Executive Vice President - Research and Development, Chief Medical Officer

Richard Chen

Vice President, General Counsel, Corporate Secretary

Stephen Moore